Richter Gedeon's 1st-qtr profits fall 46%

20 May 2007

Hungarian drugmaker Richter Gedeon says that, for the three months to March 31, 2007, its net profit was 7.98 billion forint ($43.7 million), down 46.1% on the comparable period last year. The company's diluted earnings per share were also down 46.1% to 429.0 forint.

Company chief executive Erik Bogsch said that the Hungarian government's tough measures to control the country's budget deficit, the widest in the European Union, were partly to blame for the plunge in profits. He added that the firm would reduce its investment activities in an attempt to counter the new laws that may reduce annual earnings by as much as 10.0 billion forint, according to a report on Bloomberg news. The firm also said that a drop in sales, down 3.4% to 51.01 billion forint, had impacted on its earnings for the period. Revenues from its home market were down 4.8% to 12.58 billion forint, while those from export markets fell 2.9% to 38.43 billion.

Richter's share price slipped 0.5% to 36,860 forint in trading on the Budapest stock exchange on the day of the announcement, May 8.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight